Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836795 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL2508512 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL6041032 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL828637 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL18218758 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL11127403 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL15799168 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL1361856 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337170 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337222 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117731826-A | Platelet-rich plasma hydrogel with growth factors slowly released and preparation method and application thereof | 武汉理工大学 | 2024-03-22 | — | — | CN | claimed |
| EP-4702004-A1 | NONIONIC SURFACTANTS | Detect, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20240360076-A1 | NONIONIC SURFACTANTS | DETECT INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-117177744-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| CN-115768385-A | Method for treating allergic conjunctivitis | 视觉治疗股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3371179-B1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20170362283-A1 | NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2017-12-21 | — | — | US | disclosed |
| WO-2017076998-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2017-05-11 | — | — | WO | disclosed |
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2015-10-15 | — | — | US | disclosed |
| WO-2008140973-A1 | SEMI-SYNTHETIC GLYCOPEPTIDES WITH ANTIBACTERIAL ACTIVITY | LEAD THERAPEUTICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | FLOT1, DBN1, DCTN3 | KMT2A 3717/4885SMN1; SMN2 4501/4885DGKA 450/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | KMT2A 3904/4885SMN1; SMN2 3723/4885DGKA 350/4885 |
| US-20240360076-A1 | NONIONIC SURFACTANTS | POLL, POLRMT, POLI | KMT2A 3615/4885SMN1; SMN2 1112/4885DGKA 363/4885 |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CHRM1, NPSR1, CHRM4 | KMT2A 2178/4885SMN1; SMN2 1737/4885DGKA 4639/4885 |
| US-20170362283-A1 | NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | NISCH, VIP, NGLY1 | KMT2A 4530/4885SMN1; SMN2 2507/4885DGKA 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.